GW Pharma denies provide difficulties with marijuana-primarily based drug Epidiolex following stock falls



GW Pharmaceuticals, the British maker of epileptic seizure-handle medication Epidiolex, mentioned it was not conscious of any provide difficulties associated to the cannabis-derived drug following a tweet from a patient’s father complained he could not supply the medicine.

GW’s stock was down additional than three% on Wednesday on the Nasdaq following the tweet from San Francisco Bay Location journalist Ryan Flinn, who complained that his daughter had suffered 4 seizures given that regional pharmacies and her physician had been unable to refill the prescription.

The stock declined additional early Thursday just before trimming some of the losses mid-morning.

Organization spokesman Steve Schultz mentioned there have been no provide difficulties relating to Epidiolex but did admit to some difficulties with insurance coverage businesses, according to a report Wednesday by New Cannabis Ventures.

Flinn tweeted Thursday that his daughter’s Epidiolex had arrived “after 19 calls + 338 min on telephone. Nonetheless not clear on hold up.”

United Kingdom-primarily based GW trades on the Nasdaq beneath the ticker GWPH.


Categories: Briefs, Hemp Business News, International Marijuana Enterprise News, Marijuana Stocks &amp Public Organizations, United States


Latest posts